ArticleRadiology case reports2025
Benign or malignant: FDG-avid splenic lesion in a patient with melanoma.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Though hypermetabolic metastatic splenic lesions have been reported in patients with melanoma on fluorine 18-fluorodeoxyglucose (FDG) PET-CT, FDG-avid benign splenic lesions in known cases of melanoma are exceedingly rare. These lesions can cause diagnostic confusion and potentially lead to inadvertent interventional or surgical procedures. An 82-year-old patient with a history of scalp melanoma was found to have an isolated FDG-avid splenic lesion. While it was initially diagnosed as splenic metastases on a PET-CT, it was later confirmed to be a splenic infarct secondary to an episode of bacterial endocarditis. The objective of this case report is to highlight the diagnostic dilemma posed by hypermetabolic splenic lesions in the setting of a known malignancy. This case reports emphasizes the importance of carefully considering patients' clinical history, laboratory findings, and other noteworthy differentials for hypermetabolic lesions before undertaking invasive procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.